Worldwide comparison of treatment guidelines for sore throat

Graça Coutinho¹ | Martin Duerden² | Aurelio Sessa³ | Sergio Caretta-Barradas⁴ | Attila Altiner⁵

¹Global Medical Affairs Lead Respiratory, Reckitt Benckiser, London, UK
²Medical Adviser, Centre for Medical Education, Cardiff University School of Medicine, Cardiff, UK
³Italian College of General Practitioners, Florence, Italy
⁴Respiratory Disease Center, Mexico City, Mexico
⁵Institut für Allgemeinmedizin, Universitätsmedizin Rostock, Rostock, Germany

Correspondence
Graça Coutinho, Global Medical Affairs Lead Respiratory, Reckitt Benckiser Healthcare UK Ltd., 103-105 Bath Road, Slough, Berkshire, SL1 3UH, UK.
Email: graca.coutinho@rb.com

Abstract
Introduction: Sore throat (acute pharyngitis) is globally one of the most frequent reasons for seeking healthcare. Its etiology is mostly viral. In 15%-30% of cases, group A streptococci (GAS) are detected, which may cause acute rheumatic fever. We have done a worldwide systematic review to compare diagnostic and therapeutic guidelines across countries and regions. Previous reviews of sore throat guidelines were limited to specific regions and/or language; this is the first global review.

Materials and Methods: Searches were performed in MEDLINE, EMBASE and COCHRANE (key words: sore throat, pharyngitis, tonsillitis or pharyngotonsillitis, and management, guidance, guideline or recommendation) and on the web sites of major health authorities and associated institutions from Africa, Asia, Europe, Middle East, North America, Oceania and South America.

Results: Thirty-six guidelines were identified from 26 countries. Most common are recommendations relying on the symptom- and age-based Centor or McIsaac scores. However, antibiotic treatment may be based on other symptomatic criteria; in the most extreme approach just sore throat in children. The recommendation of GAS-specific diagnostic tests is mainly limited to countries where such tests are readily available, although some countries choose not to use them. Penicillins are consistently recommended as first-line antibiotics. By contrast, guidance for symptomatic treatment is variable and mostly sparse or missing. African countries without sore throat guidelines and Asian countries bypassing them are afflicted by rising antibiotic resistance.

Conclusion: The availability of sore throat guidelines varies considerably by region and country. Moreover, important divergence is found among the guidelines regarding diagnostic and treatment criteria. This may be explained by the historical background or adoption of external guidelines, rather than local incidences of GAS infections or acute rheumatic fever. Absence of recommendations on symptomatic treatment in many guidelines is concerning, and raises issues about antimicrobial stewardship, as this should be the mainstay of sore throat management, rather than antibiotics.
Sore throat (acute pharyngitis) is prevalent worldwide and one of the most frequent complaints in children and adults requiring healthcare. The etiology of sore throat is in 70%-95% of cases viral. Rhinovirus, coronavirus and adenovirus account for at least 30% of all cases, while influenza or parainfluenza viruses are found in about 4%. Other viral pathogens in children and adults include Epstein-Barr virus, enteroviruses, respiratory syncytial virus, herpes viruses, cytomegalovirus and human immunodeficiency virus.

In approximately 15%-30% of all cases with sore throat (5%-15% in adults, 20%-30% in children), Streptococcus pyogenes (group A streptococcus, GAS) is detected. These numbers, however, also include healthy carriers and false positive test results (see below). GAS has been associated with acute rheumatic fever (ARF), which may lead to rheumatic heart disease (RHD). While similar proportions of GAS infection are reported in different regions, the incidence of ARF varies greatly; in most industrialized nations it is 100-200 times lower than in developing countries. Less frequent bacterial causes of sore throat include group C or G streptococci (about 5%), chlamydia, mycoplasma, Arcanobacterium haemolyticum, Neisseria gonorrhoeae and Corynebacterium diphtheriae (all <1%).

The clinical distinction between GAS pharyngitis (including scarlet fever) and acute pharyngitis caused by viral or other pathogens is notoriously difficult. Clinical scores have been developed to identify GAS infection, such as the Centor score for adults and the modified/McIsaac Centor score for children and adults. In the original Centor score, one point is given for each history of fever (>38°C), tonsillar exudates, tender anterior adenopathy and absence of cough. In the modified Centor score, one point is added to the original score for age 3-14 years, whereas one point is subtracted for age ≥45 years. Throat swab cultures are considered the gold standard for diagnosing GAS infection. As the results of cultures are not available before 1-2 days, rapid antigen detection tests (RADT) have been developed to identify GAS. However, false positive RADT results have been reported in about 5% of children and up to 15% of adults with acute pharyngitis. The addition of polymerase chain reaction (PCR) tests may increase sensitivity and specificity, with relatively rapid turnaround times. Yet neither RADT nor PCR or cultures can distinguish between GAS pharyngitis and GAS carriers with viral pharyngitis. The asymptomatic carriage rate of GAS is estimated to be around 6%-11% of the patient population.

The majority of adult and paediatric cases of sore throat, in particular those with viral infections that are self-limiting, do not require antibiotic treatment, but are amenable to systemic and/or local symptomatic treatments for pain, inflammation and fever. In bacterial throat infections, antibiotics may shorten the duration of symptoms by about a day. They also reduce the risk of ARF by about two thirds in communities where this complication is common.

Based on this etiological background and the different diagnostic tools and treatments, various guidelines have been developed around the world, to diagnose and treat sore throat. We have performed a systematic search to compare such guidelines across countries and regions, identify significant differences and discuss reasons for the major discrepancies.

### What’s known
- Searches for guidelines were performed in the COCHRANE Library (Systematic Reviews), EMBASE (entire database) and PUBMED (all databases, including MEDLINE) and on the internet, using the following search terms and specifications.

COCHRANE Library: SORE THROAT or PHARYNGITIS or TONSILLITIS or PHARYNGOTONSILLITIS from January 2010 through 19 May 2020 (67 items).

EMBASE: (SORE THROAT or PHARYNGITIS or TONSILLITIS or PHARYNGOTONSILLITIS) and (MANAGEMENT or GUIDANCE or GUIDELINE(S) or RECOMMENDATION(S)) in Title from 2010 through 19 May 2020 (130 items).
and the United States of America (USA), where large numbers of guidelines are available, the most recent and representative were considered. For the Western countries, in particular Europe and the United States of America (USA), where large numbers of guidelines are available, the most recent and representative published guidelines supported by the major national or regional healthcare organizations were selected.

3 | RESULTS

3.1 | Geographic origin and selection of the guidelines

A total of 36 guidelines from 26 countries were identified. Table 1 gives an overview of these guidelines by region and country; Figure 1 shows their origin on a world map. The highest number of guidelines were published in Europe; in addition to a European guideline, a selection of the most recent and relevant published guidelines from Central (Germany), Eastern (Russian Federation), Northern (Netherlands), and Sweden, Southern (Italy and Spain) and Western countries (France and United Kingdom) were included. Of a large number, the most recent and relevant published guidelines were selected from North America, including Canada, Mexico, and the USA, and Asia, i.e. China (with Hong Kong), India, Japan, Malaysia, and Thailand. Regarding the Middle East, the principal recommendations were found from Iran, Israel, Saudi Arabia, and Turkey. For South America, recommendations from Argentina and Brazil were included, in addition to a Latin American guideline. Guidance from the African continent was scarce; only two relevant, recent guidelines, one from Egypt and one from South Africa, were included. Notably, there was no guideline for the management of sore throat in Nigeria, Africa's most populated country. Two relevant guidelines were found for the Oceanian countries, one from Australia and one from New Zealand.

3.2 | Clinical diagnosis of acute pharyngitis

Although not all cases of sore throat are actually acute pharyngitis, the terms are commonly used as synonyms. Acute pharyngitis is hallmark by the acute onset of throat pain, typically with odynophagia, and signs of pharyngeal inflammation, e.g. erythema. Beyond clinical history and clinical examination, environmental and epidemiologic factors should be considered in the clinical differential diagnosis of sore throat. However, none of the retrieved guidelines provides information to distinguish acute pharyngitis from other conditions. Instead, most guidelines discuss criteria of seriousness, bacterial origin or GAS infection, to support the decision about antibiotic treatment.

3.3 | Recommendations for antibiotic treatment

All the retrieved guidelines provide criteria for antibiotic treatment, except one review of Chinese medicinal herbs for sore throat. With regards to antibiotic treatment, three groups of recommendations can be distinguished: (1) only clinical criteria, not based on the Centor score (or similar); (2) only clinical criteria, based on Centor score (or similar); (3) criteria including laboratory tests. These groups were strongly clustered according to regions. Thus, all African guidelines are based solely on clinical criteria, including neither the Centor score, nor laboratory tests. By contrast, all European and North American guidelines recommend RADT, pending on clinical signs and symptoms mostly including the Centor score, with the exception of the recommendations from the Netherlands, the United Kingdom and Mexico. While the latter two rely on the Centor score (or similar) only, the Dutch guideline considers the distinction of viral and bacterial acute pharyngitis as usually irrelevant, given the low incidence of GAS in the Netherlands. A mixed picture emerges from Asia (except China) and the Middle East, where wealthier countries, such as Japan, Israel and Saudi Arabia, but also Malaysia and a recent recommendation from Iran, include RADT in their guidelines, while the other countries, and an earlier Iranian guideline, recommend treatment according to clinical criteria, with or without using the Centor score. In China, the Special Administrative Region of Hong Kong recommends RADT, whereas Chinese National guidelines endorse antibiotic treatment based on clinical signs and symptoms only. Regarding Oceania, antibiotic treatment for sore throat is based on the Centor score in Australia, but on age, ethnic origin and socioeconomic circumstances in New Zealand.

With the exception of three guidelines from China, South Africa and the USA, all the sore throat guidelines give recommendations for antibiotic therapy. First-line treatment options are invariably penicillin-based medicines. Macrolides or cephalosporins are commonly recommended as second-line antibiotics; e.g. in case of penicillin allergy. While amoxicillin/clavulanate is infrequently recommended as second-line antibiotic in sore throat, it is the most common treatment prescribed for sore throat in children, although the guidelines recommend amoxicillin as first-line antibiotic for sore throat, where its combination with clavulanic acid offers no therapeutic advantage.
### TABLE 1 Overview of worldwide treatment guidelines

| Region | Country | Issuer of guideline or backing organizations | Criteria for antibiotic therapy | Antibiotic treatments | Symptomatic treatments |
|--------|---------|---------------------------------------------|---------------------------------|-----------------------|------------------------|
| Africa | Egypt   | World Health Organization<sup>12</sup>     | ≥ 2 of following:               | Benzathine penicillin G injection | Paracetamol             |
|        |         |                                             | • Erythema                      |                       |                        |
|        |         |                                             | • White or yellow exudate       |                       |                        |
|        |         |                                             | • Enlarged tender lymph node(s) |                       |                        |
|        | South Africa | University of Cape Town<sup>53</sup> | No cough (1) + No rhinorrhea (1) + tonsillar swelling (2) + tonsillar exudate (1) ≥ 3 with tonsillar swelling | not specified | not specified |
| Asia   | China   | Cochrane review<sup>38</sup>               | not specified                   | Antiviral, anti-asthmatic, antitussive, and fever-relieving herbs |                        |
|        | China   | Chinese Medical Association<sup>59</sup>   | Pharyngeal hyperemia, tonsillar swelling with purulent exudate, swollen and tender lymph nodes | Penicillin or first generation cephalosporins | Paracetamol; aspirin; ibuprofen |
|        | China (Hong Kong) | Centre for Health Protection<sup>8</sup> | Treatment if modified Centor score<sup>13,14</sup> ≥ 4 | First line: penicillin V or amoxicillin or cephalosporins 5-7 days; second line: clarithromycin or azithromycin | not specified |
|        | India   | University of Chennai<sup>40</sup>        | Treatment if modified Centor score<sup>13,14</sup> ≥ 4 | Penicillin | not specified |
|        | Japan   | Ministry of Health<sup>41</sup>           | RADT if modified Centor score<sup>13,14</sup> ≥ 2 or if high risk for GAS infection | Amoxicillin for 10 days | not specified |
|        | Malaysia | Ministry of Health<sup>42</sup>       | RADT based on modified Centor score<sup>13,14</sup> ≥ 2; culture or treatment if modified Centor score ≥ 4 | Ampicillin for 10 days or benzathine penicillin G injection; if allergy erythromycin or clindamycin | Paracetamol; NSAIDs; lozenges or gargles |
|        | Thailand | Mahidol University Bangkok<sup>43</sup> | Treatment if ≥ 3 of the following:               | Penicillin V or amoxicillin for 10 days; if allergy cephalaxin, roxithromycin, azithromycin, clarithromycin or clindamycin | not specified |
|         |         |                                             | • High fever in combination with sore throat |                       |                        |
|         |         |                                             | • Purulent tonsillar exudate or swollen red tonsils |                       |                        |
|         |         |                                             | • Enlarged, tender neck lymph nodes |                       |                        |
|         |         |                                             | • No symptoms of colds, such as cough or sneezing |                       |                        |
| Europe  | European Union | European Society of Clinical Microbiology and Infectious Diseases<sup>23</sup> | RADT if Centor score or modified Centor score<sup>13,14</sup> ≥ 3 | Penicillin V, 2-3x daily for 10 days | Ibuprofen; paracetamol |
|        | France  | Haute Autorité de Santé<sup>30</sup>     | RADT if modified Centor score<sup>13,14</sup> ≥ 2 | Amoxicillin 1 g 2x daily for 6 days; if allergies cefuroxime or josamycin | not specified |
|        | Germany | Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin<sup>54</sup> | Treatment if Centor score or modified Centor score<sup>13,14</sup> ≥ 3; RADT or culture only for intermediate scores | Penicillin; if allergy erythromycin | Paracetamol; ibuprofen |
|        | Italy   | Italian Panel on the Management of Pharyngitis in Children<sup>28</sup> | RADT if modified Centor score<sup>13,14</sup> ≥ 2 | Amoxicillin 50 mg/kg/d 2-3x daily for 10 days | Paracetamol; ibuprofen |

(Continues)
| Region           | Issuer of guideline or backing organizations | Criteria for antibiotic therapy | Antibiotic treatments                                                                 | Symptomatic treatments                      |
|------------------|---------------------------------------------|---------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------|
| Netherlands      | Dutch College of General Practitioners²⁶    | Not specified; antibiotics almost never indicated | Penicillin; if peritonsillar infiltrate suspected: amoxicillin/clavulanic acid        | NSAIDs not recommended as standard treatment |
| Russian Federation | Scientific Center of Children’s Health²⁵ | RADT if signs of bacterial pharyngitis; confirmation by culture unless treatment is urgent | Penicillin or amoxicillin 10 days; if allergy cephalaxin, cefadroxil, clindamycin, clarithromycin or azithromycin | NSAIDs; aspirin in adults                   |
| Spain            | Sociedad Española de Medicina de Familia y Comunitaria, Grupo de Estudio de la Infección en Atención Primaria de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, Sociedad Española de Médicos Generales y de Familia, Sociedad Española de Farmacia Familiar y Comunitaria, Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Otorrino-laringología y Patología Cérvico-Facial²⁹ | Community outbreak, immunosuppression, previous ARF, severe symptoms; RADT or treatment if not available if Centor score¹³ ≥ 3 | Penicillin V; alternatively penicillin G, amoxicillin or cefadroxil for 8-10 days; if allergy josamycin or diacetyl-midecamycin | Ibuprofen; diclofenac; flurbiprofen |
| Sweden           | Medicinal Products Agency²⁷                 | RADT if Centor score¹³ ≥ 3     | Penicillin V for 10 days; if allergy clindamycin                                        | Paracetamol; NSAIDs; aspirin                |
| United Kingdom   | National Institute for Health and Clinical Excellence³⁴ | Treatment if Centor score¹³ ≥ 3 (or use FeverPAIN score) | Penicillin V for 5-10 days; if allergy clarithromycin or erythromycin                   | Paracetamol; ibuprofen; medicated lozenges  |
| Middle East      | Iran Islamic Azad University⁴⁴             | Exudate plus enlarged tender cervical nodes | Benzathine penicillin G injection or amoxicillin                                         | not specified                              |
| Iran             | Iran University of Medical Science⁴⁵       | RADT followed by culture        | Penicillin                                                                              | not specified                              |
| Israel           | Ben-Gurion University⁴⁶                    | RADT in children and adolescents culture, if RADT negative, for acute pharyngitis except if viral features (e.g. rhinorrhea, cough, oral ulcers, hoarseness), following IDSA¹⁰⁵ | Penicillin V, amoxicillin or benzathine penicillin G; if allergy cephalaxin, cefadroxil, clindamycin, azithromycin or clarithromycin¹⁰⁵ | Acetaminophen or NSAID; aspirin to be avoided in children¹⁰⁵ |
| Saudi Arabia     | Ministry of Health⁴⁷                       | Treatment if modified Centor score¹³,¹⁴ ≥ 4; culture or RADT if score 2-3 | Penicillin V 500 mg 2x daily for 10 days; if allergy cephalaxin 500 mg 2x daily         | not specified                              |
| Turkey           | Osmangazi University⁴⁸                     | Treatment if Centor score¹³ ≥ 3 | Penicillin and erythromycin                                                              | not specified                              |
| North America    | Canada College of Family Physicians²²      | Treatment if Centor score¹³ ≥ 3; RADT if Centor score = 2 | Penicillin V                                                                              | NSAIDs                                      |
| Mexico           | Instituto Mexicano del Seguro Social¹³³   | Treatment if Ebell score¹⁰⁶ 4-5; RADT if Ebell score 1-3 | Benzathine penicillin G injection; if allergy macrolides; second line: amoxicillin/clavulanic acid | not specified                              |

(Continues)
Eighteen of the 33 guidelines that give recommendations for antibiotics advise the duration of treatment. All indicate a 10-day course of antibiotics, except the guidelines from France, Spain, the United Kingdom and China (Hong Kong), which recommend 6 days, 8-10 days, 5-10 days and 5-7 days of treatment, respectively.
3.4 | Recommendations for other treatments

Although 33 of the 36 guidelines provide recommendations regarding antibiotics, only 20 discuss other sore throat treatments. Of these 20 guidelines, 11 recommend paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of fever and pain, four recommend only NSAIDs,32,46,29,25 one recommends only paracetamol52 and one advises against the standard use of NSAIDs, because of their potential systemic side effects.26 Furthermore, four guidelines recommend topical treatments such as lozenges, gargles or sprays for analgesic treatment.42,49,34,31

The review of Chinese medicinal herbs describes antiviral, anti-asthmatic, antitussive and fever-relieving herbs as the basic elements of a traditional prescription for sore throat, detailing the therapeutic approaches for the different symptoms.38

Among the guidelines recommending symptomatic therapies, only one, from Australia,55 specifies the duration of the treatment (ie, 1 to 2 days).

4 | DISCUSSION

Several previous reviews have analysed guidelines for the management of sore throat in children and adults.65-68 These reviews include guidelines published up to 2006,65 2010,66 201268 and 2015 (date of latest reference),67 respectively. The major limitations of these reviews are the restrictions to North American and European guidelines,65-67 to English language67,68 and to published literature.66,67 To our knowledge, the present work is the first review of sore throat guidelines that has no geographic or linguistic restrictions, and includes guidelines not published in the literature. The fact that guidelines from either primary care or other fields of expertise were considered contributed to the diversity of the recommendations.

Major limitations of the present review include the restriction of literature searches to a limited string of key words and a 10-year limit. The use of wider criteria and of iterative techniques would have allowed identifying a larger number of guidelines. Guidelines published more than 10 years ago are likely to be out of date and no longer in use. The set of key words, which were used across different databases to increase the reach of the searches, was chosen to correspond to the words a general practitioner might use to search for up to date guidelines. The principal restraint for the internet searches was the use of English as principal language, although limited internet searches were also performed in Arabic, Chinese, French, Russian, Spanish, German and Portuguese; the first six correspond to the official languages of the World Health Organization. Although guidelines in any language were considered, the search methods may have introduced a bias in favour of the Western industrialized countries. Also in these areas guidelines tend to be published more frequently, both in the scientific literature and on the internet.

The review of the guidelines reveals important divergences regarding diagnostic and antibiotic treatment criteria in different countries. A large variety of clinical and/or laboratory criteria are proposed to identify and treat GAS infection. The reliance on merely clinical criteria in many of the recent guidelines is surprising, as few patients present with the typical signs and symptoms of GAS pharyngitis described in the guidelines, and neither clinical history nor physical examination...
can differentiate between GAS infection and other causes of sore throat. While lab tests may not be readily at hand in all regions (e.g. Africa), guidelines of many countries where the tests are available choose not to use them (e.g. several Middle East and Asian countries, Australia and New Zealand). Rather than by the availability of the lab tests, the large variability in the diagnostic criteria may be explained by the uncertainty of the scientific basis that underlies the different recommendations. In a well-documented ARF outbreak in the late eighties in Utah (USA), half of the cases did not have any symptoms of sore throat, and swab tests were negative in a large proportion of the patients. Furthermore, regarding the laboratory tests, neither RADT nor bacterial cultures can differentiate individuals with GAS pharyngitis from GAS carriers with intercurrent viral pharyngitis.

Comparing the guidelines from different regions, the most unexpected observation is that their differences in the antibiotic treatment criteria do generally not reflect the large variations in the risk of GAS infection and its complications across the world. While ARF and RHD have declined worldwide, they still remain major a cause of morbidity and mortality in some regions. The African, South-East Asia and Western Pacific regions are most affected, accounting for 84% of all prevalent cases and 80% of all estimated deaths because of RHD globally in 2015. Yet, with the exception of New Zealand, the guidelines from Africa (Egypt), South-East Asia (India, Malaysia, Thailand) and Western Pacific (Australia, New Zealand) appear to mirror those of Europe and North America, where the incidence of ARF and the prevalence of RHD are about 100 times lower.

It might be argued that the systematic antibiotic treatment of sore throat has enabled reduction in the incidence of complications from GAS in the developed nations. If so, these guidelines would be particularly beneficial for the high risk countries. Yet, there is no evidence that the near disappearance of ARF and RHF in the industrialized countries, such as the United States of America, since the beginning of the last century was related to the wide use of antibiotics since the early fifties. Furthermore, the appropriate duration of antibiotic therapy for streptococcal pharyngitis is controversial regarding clinical efficacy, bacteriological eradication and complication rates. Notwithstanding these considerations, many guidelines give no indication for the duration of antibiotics, and only few suggest a shorter treatment than the 10-day standard regimen.

Based on the data from older trials, antibiotics can significantly reduce the incidence of ARF and other complications (including otitis media and tonsillar abscess), in patients with acute pharyngitis. However, in high-income countries, where not only the overall incidence of GAS infections is low, but also the rates of complications from the latter are reduced, the number needed to treat may exceed an acceptable limit to make treatment worthwhile to reduce these complications. Any use of antibiotics, but especially widespread and excessive use, and long treatment durations, increase the risk of drug resistance. Rising antimicrobial resistance threatens the national health care systems and economics, including those of the industrialized countries. To prevent the unnecessary use of antibiotics, national and international treatment guidelines are of prime importance. Whilst most prescribers in the USA and in Europe have easy access to antibiotic guidelines, many do not trust these guidelines. Only a minority of physicians in the USA and in many European countries follow current guidelines to treat sore throat and prevent ARF. By contrast, effective implementation of appropriate guidelines was shown to improve general practitioners’ adherence and reduce unnecessary and inappropriate use of antibiotics.

In African countries where no national guidelines for the treatment of acute pharyngitis exist, such as Nigeria, antibiotics are prescribed empirically for most patients presenting with sore throat. Such practices may fuel deadly drug-resistant infections, such as bacterial pneumonia and diarrhoea. Today, a large proportion of salmonella infections have become resistant to the most widely available antibiotics in Nigeria and Kenya. In Asian countries where many people take antibiotics for infections without any prescription, alarming levels of multidrug resistance have emerged. Thus, rather than helping vulnerable populations plagued by life-threatening infections, such as HIV, tuberculosis and certain respiratory viruses, excessive and irrational uses of antibiotics seriously compound their healthcare issues.

Besides GAS, group B, C or G beta-hemolytic streptococci and Fusobacterium necrophorum have been identified in sore throat. There is some doubt about whether they are truly pathogenic or require antibiotic treatment. Some of these infections have on rare occasions been associated with supplicative complications, e.g. peritonsillar abscess (quinsy), requiring specialist care (such as surgical drainage) and antibiotic treatment. Serious complications of the fusobacteria, such as thrombophlebitis of the internal jugular vein (Lemierre’s syndrome), are exceedingly rare. Beta-hemolytic streptococci other than GAS are not associated with ARF and RHD.

While well-targeted antibiotic treatments may prevent the spread of GAS pharyngitis, reduce cases of ARF where this is prevalent, and help treating supplicative complications of bacterial infections, their overall efficacy in reducing the duration of symptoms of sore throat is modest. Analgesics and in particular NSAIDs are more effective than antibiotics to treat sore throat symptoms such as pain and fever. Given the fact that symptomatic therapy represents the primary medical need for most patients, it is striking that many guidelines only provide guidance for antibiotic treatment of sore throat. Furthermore, besides throat pain and fever, acute pharyngitis may present with a variety of other symptoms, such as oral ulcers, difficulties in swallowing, hoarse voice, cough, rhinorrhea, conjunctivitis, painful and swollen glands, skin rash, gastrointestinal symptoms and malaise. The only guidance, however, that discusses symptoms other than pain and fever is the review of Chinese traditional medicines. Although the prolonged use of analgesics is associated with a risk of serious side effects, just a single guideline specifies their duration.

In conclusion, the important differences observed in the worldwide treatment guidelines for sore throat do not seem to have a rational basis. While the guidelines may reflect the historical background (such as the high prevalence of ARF in the USA during the 19th century) or the adoption of recommendations from external guidelines (e.g. by African, South-East Asia and Western Pacific countries), they have often not been adapted to the actual,
present-day local incidence of GAS pharyngitis or its complications. Yet wide variations are also observed within a single region, such as Europe. Some variation may reflect an evolving understanding of this common disease and reflect uncertainty. Another explanation might be related to the issuers' opinions and priorities, rather than scientific evidence, and these may be country specific or related to differences in systems of healthcare. 104 For healthcare providers, the lack of harmonization or consistency is likely to impact on the adoption of the guidelines and hence the quality of care. 82,105

Implementation of appropriate treatment guidelines can increase physicians' adherence and correct use of the available treatments. Although symptomatic treatments, rather than antibiotics, are the mainstay of the therapeutic management for sore throat, recommendations on symptomatic treatment are missing in many guidelines. This may cause unnecessary suffering and drive the ineffective use of antibiotics. As sore throat is one of the commonest reasons for using antibiotics worldwide, these omissions impede current international strategies to reduce antibiotic use as part of antimicrobial stewardship. 87,88

ACKNOWLEDGEMENTS

We thank Don Dreher from Totzke & Dreher Scientific SA for his assistance with the literature search, drafting and formatting of the manuscript.

DISCLOSURES

G. A. Coutinho is an employee of Reckitt Benckiser Health Care UK Ltd. (RB), which is involved in the prevention and treatment of infectious diseases. M. Duerden, A. Sessa, S. Caretta-Barradas and A. Altiner are members of the Global Respiratory Infection Partnership (GRIP), which receives an educational grant from RB, RB funded Totzke & Dreher Scientific SA, Geneva, Switzerland to assist with the literature search, drafting and formatting of the manuscript.

ORCID

Graça Coutinho https://orcid.org/0000-0002-9580-5949

REFERENCES

1. Gerber MA. Diagnosis and treatment of pharyngitis in children. Pediatr Clin North Am. 2005;52:729-747. vi. http://www.ncbi.nlm.nih.gov/pubmed/15925660.
2. Somro A, Akram M, Khan MI, et al. Pharyngitis and sore throat: a review. Afr J Biotech. 2011;10:6190–6197. http://www.ajol.info/index.php/ajbj/article/view/94560/83932.
3. Cots JM, Alos JL, Barcena M, et al. Recommendations for management of acute pharyngitis in adults. Acta Otorrinolaringol Esp. 2015;66:159-170. http://www.ncbi.nlm.nih.gov/pubmed/25772389.
4. Worrall G. Acute sore throat. Can Fam Phys Medecin de famille canadien. 2011;57:791-794. http://www.ncbi.nlm.nih.gov/pubmed/21753103.
5. Bisno AL. Acute pharyngitis. New Engl J Med. 2001;344:205-211. http://www.ncbi.nlm.nih.gov/pubmed/11172144.
6. ANVISA. Faringites e Amigdalites estreptocócicas. Agencia Nacional de Vigilancia Sanitaria (Brazil) 2008; Tratamento das principais infecções comunitárias e relacionadas à assistência à saúde e a profilaxia antimicrobiana em cirurgia. www.anvisa.gov.br/servico.saude/controle_remedio/cursos/atm_racional/modulo_03/comunitarias10.htm.
7. CDC. Pharyngitis (Strep Throat). Centers for Disease Control and Prevention (United States of America). 2018; Group A Streptococcal (GAS) Disease. http://www.cdc.gov/groupastrep/diseases-hcp/strep-throat.html Accessed 19 May, 2020.
8. CHP (Centre for Health Protection) of the Hong Kong Special Administrative Region, Advisory Group on Antibiotic Stewardship Programme in Primary Care, Chan AMW, et al. Antibiotic management of acute pharyngitis in primary care. Hong Kong Med J. 2019;25:58-63. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L2001930608. https://doi.org/10.12809/hkmj187544.
9. Seckeler MD, Hoke TR. The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. Clin Epidemiol. 2011;3:67-84. http://www.ncbi.nlm.nih.gov/pubmed/21386976.
10. Karthikeyan G, Guilherme L. Acute rheumatic fever. Lancet. 2018;392:161-174. http://www.ncbi.nlm.nih.gov/pubmed/30025809.
11. Weil-Olivier C. Rheumatic fever. Orphanet encyclopedia 2004; January 2004. http://www.orpha.net/data/patho/GB/uk-RF.pdf Accessed 19 May, 2020.
12. Wessels MR. Clinical practice. Streptococcal pharyngitis. New Engl J Med. 2011;364:648-655. http://www.ncbi.nlm.nih.gov/pubmed/21323542.
13. Centor RM, Witherspoon JM, Dalton HP, Brody CE, Link K. The diagnosis of strep throat in adults in the emergency room. Med Decis Making. 1981;1:239-246. http://www.ncbi.nlm.nih.gov/pubmed/6763125.
14. McIsaac WI, White D, Tannenbaum D, Low DE. A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ. 1998;158:75-83. http://www.ncbi.nlm.nih.gov/pubmed/9475915.
15. Rao A, Berg B, Quezada T, et al. Diagnosis and antibiotic treatment of group a streptococcal pharyngitis in children in a primary care setting: impact of point-of-care polymerase chain reaction. BMC Pediatr. 2019;19:24. http://www.ncbi.nlm.nih.gov/pubmed/30651115.
16. Gerber MA, Shulman ST. Rapid diagnosis of pharyngitis caused by group A streptococci. Clin Microb Rev. 2004;17:571-580. Table of contents. http://www.ncbi.nlm.nih.gov/pubmed/15258094.
17. Fox C, Fitzpatrick P. The use of a rapid antigen detection test for beta haemolytic group a streptococcus to aid the management of pharyngitis and tonsillitis in an Irish tertiary paediatric emergency department. Arch Dis Child. 2019;104(Fox C.; Fitzpatrick P) Children's University Hospital. Temple Street, Dublin, Ireland) A110. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L628695914. https://doi.org/10.1136/archdischild-2019-epa.256.
18. Cohen JF, Bertille N, Cohen R, Chalumeau M. Rapid antigen detection test for group A streptococcus in children with pharyngitis. Cochrane Database Syst Rev. 2016;7:CD010502. http://www.ncbi.nlm.nih.gov/pubmed/27374000.
19. Johnson DR, Kaplan EL. False-positive rapid antigen detection test results: reduced specificity in the absence of group A streptococci in the upper respiratory tract. J Infect Dis. 2001;183:1135-1137. http://www.ncbi.nlm.nih.gov/pubmed/11237843.
20. Olivier J, Malliya Wadu E, Pierce N, Moreland NJ, Williamson DA, Baker MG. Group A Streptococcus pharyngitis and pharyngeal carriage: a meta-analysis. PLoS Negl Trop Dis. 2018;12:e0006335. http://www.ncbi.nlm.nih.gov/pubmed/29554121.
21. Klimek L, Sperl A. Pharmacology sore throat therapy according to current guidelines. Med Monatsschr Pharm. 2015;38:503-508.
http://www.embase.com/search/results?subaction=viewrecord &from=export&id=L607328759.

22. Spinks A, Glasziou PP, Del Mar CB. Antibiotics for sore throat. Cochrane Database Syst Rev. 2013;11:CD000023. http://www.ncbi.nlm.nih.gov/pubmed/24190439.

23. ESCMID STGG, Pelucchi C, Grigoryan L, et al. Guideline for the management of acute sore throat. Eur J Clin Microbiol Infect Dis. 2012;18:1-28. http://www.ncbi.nlm.nih.gov/pubmed/22432746.

24. Wächtlér H, Chenot JF. Guidelines for the management of sore throat from the German Society of General Practice and Family Medicine. HNO. 2011;59:480-484. https://doi.org/10.1007/s00106-011-2263-6. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L51326524.

25. Kulichenko TB. Diagnosis and treatment of acute streptococcal pharyngitis in children. Pediatricheskaya farmakologiya (Pediatric pharmacology). 2015;12:104-111. http://www.pedpharma.ru/index.php/jour/article/view/478/0.

26. de Jongh E, Opstelten W. Revision of the Dutch College of General Practitioners practice guideline ‘Acute sore throat’. Nederlands tijdschrift voor geneeskunde. 2015; 159(de Jongh E.; Opstelten W.) Nederlands Huisartsen Genootschap, afdeling Richtlijnontwikkeling en Wetenschap, Utrecht) A9456. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L607566440.

27. MPA. Handläggning av faryngotonsillitier i öppenvård – ny rekommendation. Information från läkemedelsverket. 2012;6. http://lakemedelsverket.se/faryngotonsillit.

28. Chiappini E, Bortone B, Di Mauro G, et al. Choosing wisely: the top-5 Recommendations from the Italian Panel of the National Guidelines for the Management of Acute Pharyngitis in children. Clin Ther. 2017;39:646-649. https://doi.org/10.1016/j.clinthera.2017.01.021. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L61432788.

29. Cots Yago JM, Álós Cortés J-I, Bárcena Caamaño M, et al. Guía clínica para el manejo de la faringoamigdalitis aguda del adulto. Farmacéuticos Comunitarios. 2015;7:20-31. http://www.farmaeuticoscomunitarios.org/system/files/journals/824/articles/faringoamigdalitis_0.pdf.

30. HAS. Antibiothérapie des infections respiratoires hautes. Haute Autorité de Santé 2015; Contenu métier DataSet. http://www.has-sante.fr/upload/docs/application/pdf/2016-02/dataset_-_contenu_metier_infections_respiratoires_hautes.pdf.

31. NICE. Sore throat (acute): antimicrobial prescribing. National Institute for Health and Care Excellence 2018; NICE guideline. http://www.nice.org.uk/guidance/ng84.

32. Worrall G. Acute sore throat. Can Fam Phys. Medecin de famille canadien. 2007;53:1961-1962. http://www.ncbi.nlm.nih.gov/pubmed/18000276.

33. Villaseñor IR. Instituto Mexicano del Seguro Social (Mexico). Uso de antimicrobianos en infecciones agudas de vías respiratorias altas. Revista Médica del IMSS. 2005;43.

34. CENETEC. Diagnóstico y tratamiento de faringoamigdalitis aguda. Centro Nacional de Excelencia Tecnológica en Salud 2015; Evidencias y Recomendaciones. IMSS-073-08 www.cenetc-difusion.com/CMGPC/IMSS-073-08/ER.pdf.

35. Choby BA. Diagnosis and treatment of streptococcal pharyngitis. Am Fam Physician. 2009;79:383-390. http://www.ncbi.nlm.nih.gov/pubmed/19275067.

36. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research; endorsed by the American Academy of Pediatrics. Circulation. 2009;119:1541-1551. http://www.ncbi.nlm.nih.gov/pubmed/19246689.

37. Randel A. Infectious disease society of A. IDSA updates guideline for managing group a streptococcal pharyngitis. Am Fam Physician. 2013;88:338-340. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L370221396.

38. Huang Y, Wu T, Zeng L, Li S. Chinese medicinal herbs for sore throat. Cochrane Database Syst Rev. 2012;3:CD004877. http://www.ncbi.nlm.nih.gov/pubmed/22419300.

39. Cao B. Chinese Medical Association (CMA). Guidelines for Primary Diagnosis and Treatment of Acute Upper Respiratory Tract Infection (2018). Chin J Gen Pract. 2019;18:422-426. http://www.mdscientific.com/guideline/article.do?id=122901c001ea9356.

40. Vasudevan J, Mannu A, Ganavi G. McIsaac modification of center score in diagnosis of streptococcal pharyngitis and antibiotic sensitivity pattern of beta-hemolytic Streptococci in Chennai, India. Indian Pediatr. 2019;56:49-52. http://www.ncbi.nlm.nih.gov/pubmed/30806362.

41. MOH Japan. Acute Respiratory Tract Infection (ARTI) - Pharyngitis. Ministry of Health, Labour and Welfare 2017; Manual of Antimicrobial Stewardship (1st ed.). http://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkouyokuu/0000193504.pdf.

42. MOH Malaysia. Management of sore throat. Ministry of Health Malaysia 2003; Clinical Practice Guidelines. www.moh.gov.my/moh/attachments/4001.pdf.

43. Mahidol University. Pharyngitis/tonsillitis. Antibiotic Smart Use (ASU) Guideline 2015; Guidelines for caring for patients with upper respiratory tract infections. For patients without low immunity. Ramathibodi Hospital. http://med.mahidol.ac.th/ramapharmacy/sites/default/files/public/GuideLine%20ASU%20Ram athibodi%20Mar%202015.pdf.

44. Nasirian H, Tarvij Esliami S, Matini E, Bayesh S, Omaareey Y. A clinical decision rule for streptococcal pharyngitis management: an update. J Lab Phys. 2017;9:116-120. http://www.ncbi.nlm.nih.gov/pubmed/28367027.

45. Behnamfar Z, Shahkarami V, Sohrabi S, Aghdam AS, Afzali H. Cost and effectiveness analysis of the diagnostic and therapeutic approaches of group A Streptococcus pharyngitis management in Iran. J Fam Med Prim Care. 2018;9:2942-2949. http://www.ncbi.nlm.nih.gov/pubmed/31681672.

46. Urkin J, Allenbogen M, Friger M, Vinker S, Reuveni H, Elahayani A. Acute pharyngitis: Low adherence to guidelines highlights need for greater flexibility in managing paediatric cases. Acta Paediatr. 2013;102:1075-1080. https://doi.org/10.1111/apa.12364. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L52727608.

47. AMR. National antimicrobial therapy guidelines for community and hospital acquired infections in adults. Ministry of Health (Saudi Arabia) 2018; Antimicrobial Stewardship Subcommittee of the National Antimicrobial Resistance Committee. http://www.moh.gov.sa/en/CCC/health/regulations/Documents/Natio nal%20Antimicrobial%20Guidelines.pdf.

48. Ayranci U, Akgun Y, Unluoglu I, Kiremitci A. Antibiotic prescribing patterns for sore throat infections in a university-based primary care clinic. Ann Saudi Med. 2005;25:22-28. http://www.ncbi.nlm.nih.gov/pubmed/15822490.

49. Lopardo G, Calmaggi A, Clara L, et al. Artículo especial. Consenso sobre diagnóstico y tratamiento de infecciones de vías respiratorias altas. Medicina (Buenos Aires). 2012;72:484-494. www.medicalinabuenosaires.com/PMID/23241293.pdf.

50. ABORL-CFF. I Campanha sobre uso de antibióticos em infeccções de vias aéreas superiores. Associação Brasileira de
Otorrinolaringologia e Cirurgia Cérvico-Facial 2017; Consenso Antibiótico v6. https://www.aboriccf.org.br/imageBank/Consenso_Antibiotico-v6.pdf.

51. API. Faringitis aguda. Asociación Panamericana de Infectología 2009; Bases para el manejo racional de las infecciones respiratorias agudas. http://www.studocu.com/es/document/universidad-tecnologica-de-chile/familiar-del-adulto/resumenes/bases-para-el-manejo-racional-de-las-infecciones-respiratorias-agudas/4209433.

52. WHO. Integrated Management of Childhood Illness (IMCI). World Health Organization 2010; Country IMCI chart booklet Egypt. Rev. 2010. www.emro.who.int/child-health/IMCI/adaptation-countries.

53. Engel ME, Cohen K, Gounden R, et al. The Cape Town Clinical Decision Rule for streptococcal pharyngitis in children. Pediatr Infect Dis J. 2017;36:250-255. http://www.ncbi.nlm.nih.gov/pubmed/27870815.

54. Sadoh WE, Akinsete AM. Physicians management of sore throat in Nigeria. J Fam Pract. 2013;40:1-5. http://www.ajol.info/index.php/njp/article/view/83399.

55. NSW. Infants and Children: Acute Management of Sore throat. New South Wales Health (Australia) 2014; Guideline GL2014_021; www.health.nsw.gov.au/pds/ActivePDSDocuments/GL2014_021.pdf Accessed 19 May, 2020.

56. NHF. Group A Streptococcal Sore Throat Management. National Heart Foundation (New Zealand) 2019; Guideline Update 2019. http://www.heartfoundation.org.nz/shop/heart-healthcare/non-stock-resources/gas-sore-throat-rheumatic-fever-guide-line.pdf.

57. Stephenson KN. Acute and chronic pharyngitis across the lifespan. Lippincott's Prim Care Pract. 2000;4:471-489. http://www.ncbi.nlm.nih.gov/pubmed/11933437.

58. Sadowski A, Dougherty J. Not all sore throats are pharyngitis. Clin Pract Cases Emerg Med. 2017;1:280-282. http://www.ncbi.nlm.nih.gov/pubmed/29849338.

59. Martin JM. Pharyngitis and streptococcal throat infections. Pediatr Ann. 2010;39:22-27. http://www.ncbi.nlm.nih.gov/pubmed/20151621.

60. BMJ. Acute pharyngitis. Br Med J. 2019; Best Practice, Topics (engl). http://bestpractice.bmj.com/topics/en/us-5/.

61. Vincent MT, Celestin N, Hussain AN. Pharyngitis. Am Fam Physician. 2004;69:1465-1470. http://www.ncbi.nlm.nih.gov/pubmed/15053411.

62. Steinhoff MC, Abd el Khalek MK, Khalaf N, et al. Effectiveness of clinical guidelines for the presumptive treatment of streptococcal pharyngitis in Egyptian children. Lancet. 1997;350:918-921. http://www.ncbi.nlm.nih.gov/pubmed/9314870.

63. Sadoh WE, Akinsete AM. Physicians management of sore throat in Benin City. Nigeria. Nigerian journal of clinical practice. 2009;12:407-411. http://www.ncbi.nlm.nih.gov/pubmed/20329682.

64. AIFA. L’uso dei farmaci in Italia. Agenzia Italiana del Farmaco 2019; Rapporto nazionale anno 2018 (Sezione 2 - L’uso dei farmaci nelle popolazioni fragili). http://www.aifa.gov.it/documents/201420/Rapporto_OsMed_2018.pdf/c9eb791f-b791-2759-4a9e-e56e1348a976.

65. Matthey J, De Meyere M, van Driel ML, De Sutter A. Differences among international pharyngitis guidelines: not just academic. Ann Fam Med. 2007;5:436-443. http://www.ncbi.nlm.nih.gov/pubmed/17893386.

66. Chiappini E, Regoli M, Bonsignori F, et al. Analysis of different recommendations from international guidelines for the management of acute pharyngitis in adults and children. Clin Ther. 2011;33:48-58. https://doi.org/10.1016/j.clinthera.2011.02.001. http://www.embase.com/search/results?subact=viewrecord&from=expor t&id=L361419605.

67. Hildreth AF, Takhar S, Clark MA, Hatten B. Evidence-based evaluation and management of patients with pharyngitis in the emergency department. Emerg Med Proc. 2015;17:1-16. http://www.embase.com/search/results?subact=viewrecord&from=export &t&id=L60665549.

68. Hoare KJ, Ward E, Arroll B. International sore throat guidelines and international medical graduates: a mixed methods systematic review. J Prim Health Care. 2016;8:20-29. https://doi.org/10.1071/HC15032. http://www.embase.com/search/results?subact=viewrecord&from=export&id=L17369799.

69. Martin JM. The mysteries of streptococcal pharyngitis. Curr Treat Opt Pediatr. 2015;1:180-189. http://www.ncbi.nlm.nih.gov/pubmed/26146604.

70. CDC. Acute rheumatic fever–Utah. Morb Mortal Wkly Rep. 1987;36:108-110. 15. http://www.ncbi.nlm.nih.gov/pubmed/3102935.

71. Berkley J. Management of pharyngitis: should America fall in line with the rest of the developed world? Circulation. 2018;138:1920-1922. https://doi.org/10.1161/CIRCULATIONAHA.118.035900. http://www.embase.com/search/results?subact=viewrecord &from=export&id=L62707963.

72. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, and national burden of rheumatic heart disease, 1990–2015. New Engl J Med. 2013;377:713-722. http://www.ncbi.nlm.nih.gov/pubmed/28834488.

73. WHO. Rheumatic fever and rheumatic heart disease. World Health Organization 2018; Report by the Director-General (A71/25). http://apps.who.int/ebwha/pdf_files/WHA71/A71_25-en.pdf.

74. Altamimi S, Khalil A, Khalaiwi KA, Milner R, Pusic MV, Al Othman MA. Short versus standard duration antibiotic therapy for acute streptococcal pharyngitis in children. Cochrane Database Syst Rev. 2012;CD004872.pub3. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004872.pub3/full.

75. Schwartz RH, Kim D, Martin M, Pichichero ME. A reappraisal of the minimum duration of antibiotic treatment before approval of return to school for children with streptococcal pharyngitis. Pediatr Infect Dis J. 2015;34:1302-1304. http://www.ncbi.nlm.nih.gov/pubmed/26295745.

76. Moore M, Stuart B, Hobbs FR, et al. Influence of the duration of penicillin prescriptions on outcomes for acute sore throat in adults: the DESCARTE prospective cohort study in UK general practice. Br J Gen Pract. 2017;67:e623-e633. http://www.ncbi.nlm.nih.gov/pubmed/28808076.

77. Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14:13. http://www.ncbi.nlm.nih.gov/pubmed/24405683.

78. O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resis. 2014. http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf.

79. Raymond B. Five rules for resistance management in the antibiotic apocalypse, a road map for integrated microbial management. Evol Appl. 2019;12:1079-1091. http://www.ncbi.nlm.nih.gov/pubmed/31297143.

80. Tacconelli E, Pezanni MD. Public health burden of antimicrobial resistance in Europe. Lancet Infect Dis. 2019;19:4-6. http://www.ncbi.nlm.nih.gov/pubmed/30409682.

81. Elias C, Moja L, Mertz D, Leeb M, Forte G, Magrini N. Guideline recommendations and antimicrobial resistance: the need for a change. BMJ Open. 2017;7:e016264. http://www.ncbi.nlm.nih.gov/pubmed/28751488.

82. IOM. Clinical practice guidelines we can trust. Institute of Medicine (US) 2011; Washington, DC: The National Academies Press.
94. Nepal G, Bhatta S. Self-medication with Antibiotics in WHO Southeast Asian Region: a systematic review. Cureus. 2018;10:e2428. http://www.ncbi.nlm.nih.gov/pubmed/29876150.

95. Qu J, Huang Y, Lv X. Crisis of antimicrobial resistance in China: now and the future. Front Microbiol. 2019;10:2240. http://www.ncbi.nlm.nih.gov/pubmed/31611863.

96. Yam ELY, Hsu LY, Yap EP, et al. Antimicrobial resistance in the Asia Pacific region: a meeting report. Antimicrob Resist Infect Control. 2019;8:202. http://www.ncbi.nlm.nih.gov/pubmed/31890158.

97. Whidbey C, Burnside K, Martinez RM, et al. A hyperhemolytic/hyperpigmented group B Streptococcus strain with a CovR mutation isolated from an adolescent patient with sore throat. Clin Res Infect Dis. 2015;2. http://www.ncbi.nlm.nih.gov/pubmed/26913295.

98. Marchello C, Ebell MH. Prevalence of Group C Streptococcus and fusobacterium necrophorum in patients with sore throat: a meta-analysis. Ann Fam Med. 2016;14:567-574. http://www.ncbi.nlm.nih.gov/pubmed/28376443.

99. Naik TB, Nadagir SD, Biradar A. Prevalence of beta-hemolytic Streptococci Groups A, C, and G in patients with acute pharyngitis. J Lab Phys. 2016;8:45-49. http://www.ncbi.nlm.nih.gov/pubmed/27013813.

100. Kenealy T. Sore throat. BMJ Clin Evid. 2007. 2007. http://www.ncbi.nlm.nih.gov/pubmed/19450346.

101. Thomas M, Del Mar C, Glasziou P. How effective are treatments other than antibiotics for acute sore throat? Br J Gen Pract. 2000;50:817-820. http://www.ncbi.nlm.nih.gov/pubmed/11127175.

102. de Looze F, Sheppard A, Smith AB. Locally delivered Flurbiprofen 8.75 mg for treatment and prevention of sore throat: a narrative review of clinical studies. J Pain Res. 2019;12:3477-3509. http://www.ncbi.nlm.nih.gov/pubmed/31920372.

103. Pharyngitis WMR. Pharyngitis and scarlet fever. In Ferretti JJ, Stevens DL, Fischetti VA, eds. Streptococcus pyogenes: basic biology to clinical manifestations. Oklahoma City (OK). 2016. http://www.ncbi.nlm.nih.gov/pubmed/26866221.

104. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527-530. http://www.ncbi.nlm.nih.gov/pubmed/10024268.

105. Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group a streptococcal pharyngitis: 2012 update by the infectious diseases society of America. Clin Infect Dis. 2012;55:e86-e102. https://doi.org/10.1093/cid/cis642. http://www Embase.com/search/results?subaction=viewrecord&from=export&id=L365937443.

106. Ebell MH. Strep throat. Am Fam Physician. 2003;68:937-938. http://www.ncbi.nlm.nih.gov/pubmed/13678144.

107. Drouhy P. A large blank world map with oceans marked in blue. Wikimedia Commons, the free media repository 2019; SVG file, without Antarctica (30 May 2019). http://commons.wikimedia.org/wiki/File:A_large_blank_world_map_with_oceans_marked_in_blue.svg#File Accessed 28 November, 2019.

How to cite this article: Coutinho G, Duerden M, Sessa A, Caretta-Barradas S, Altiner A. Worldwide comparison of treatment guidelines for sore throat. Int J Clin Pract. 2021;75:e13879. https://doi.org/10.1111/ijcp.13879